

Randomized Withdrawal Study of Patients With Symptomatic Hypotension Responsive to Droxidopa

Hypertension

65, 101-107

DOI: [10.1161/hypertensionaha.114.04035](https://doi.org/10.1161/hypertensionaha.114.04035)

Citation Report

#	ARTICLE	IF	CITATIONS
1	New clinical trials for nonmotor manifestations of Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 1490-1504.	2.2	81
2	Therapeutic advances in multiple system atrophy and progressive supranuclear palsy. <i>Movement Disorders</i> , 2015, 30, 1528-1538.	2.2	17
3	Neurogenic orthostatic hypotension – management update and role of droxidopa. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 915.	0.9	4
4	Prospects for Droxidopa in Neurogenic Orthostatic Hypotension. <i>Hypertension</i> , 2015, 65, 34-35.	1.3	4
5	Droxidopa: A Review of Its Use in Symptomatic Neurogenic Orthostatic Hypotension. <i>Drugs</i> , 2015, 75, 197-206.	4.9	39
6	Current Pharmacological Management of Hypotensive Syndromes in the Elderly. <i>Drugs and Aging</i> , 2015, 32, 337-348.	1.3	9
7	Diagnosing and treating neurogenic orthostatic hypotension in primary care. <i>Postgraduate Medicine</i> , 2015, 127, 702-715.	0.9	13
8	Clinical Relevance of Orthostatic Hypotension in Neurodegenerative Disease. <i>Current Neurology and Neuroscience Reports</i> , 2015, 15, 78.	2.0	15
9	Neurogenic orthostatic hypotension: roles of norepinephrine deficiency in its causes, its treatment, and future research directions. <i>Current Medical Research and Opinion</i> , 2015, 31, 2095-2104.	0.9	22
10	Droxidopa for neurogenic orthostatic hypotension. <i>Expert Opinion on Orphan Drugs</i> , 2015, 3, 1479-1490.	0.5	5
11	Droxidopa in neurogenic orthostatic hypotension. <i>Expert Review of Cardiovascular Therapy</i> , 2015, 13, 875-891.	0.6	80
12	MRI-based Annual Cerebellar Volume Atrophy Rate as a Biomarker of Disease Progression in Patients with Cerebellar Degeneration. <i>Journal of St Marianna University</i> , 2016, 7, 117-124.	0.1	2
13	Toward disease modification in multiple system atrophy: Pitfalls, bottlenecks, and possible remedies. <i>Movement Disorders</i> , 2016, 31, 235-240.	2.2	9
14	Safety and Durability of Effect with Long-Term, Open-Label Droxidopa Treatment in Patients with Symptomatic Neurogenic Orthostatic Hypotension (NOH303). <i>Journal of Parkinson's Disease</i> , 2016, 6, 751-759.	1.5	32
15	Atypical parkinsonism " new advances. <i>Current Opinion in Neurology</i> , 2016, 29, 480-485.	1.8	16
16	Droxidopa for orthostatic hypotension. <i>Journal of Hypertension</i> , 2016, 34, 1933-1941.	0.3	21
17	Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension. <i>BMC Neurology</i> , 2016, 16, 143.	0.8	3
18	Pathophysiology and Treatment of Orthostatic Hypotension in Parkinsonian Disorders. <i>Current Treatment Options in Neurology</i> , 2016, 18, 28.	0.7	11

#	ARTICLE	IF	CITATIONS
19	Diuretics for Hypertension: A Review and Update. American Journal of Hypertension, 2016, 29, 1130-1137.	1.0	104
20	Long-term safety of droxidopa in patients with symptomatic neurogenic orthostatic hypotension. Journal of the American Society of Hypertension, 2016, 10, 755-762.	2.3	22
21	Efficacy of Servo-Controlled Splanchnic Venous Compression in the Treatment of Orthostatic Hypotension. Hypertension, 2016, 68, 418-426.	1.3	58
22	Effects of the novel norepinephrine prodrug, droxidopa, on ambulatory blood pressure in patients with neurogenic orthostatic hypotension. Journal of the American Society of Hypertension, 2016, 10, 819-826.	2.3	21
23	New Horizons in orthostatic hypotension: Table 1.. Age and Ageing, 2017, 46, 168-174.	0.7	21
24	Nonmotor symptoms in Parkinson's disease: are we still waiting for the honeymoon?. European Journal of Neurology, 2016, 23, 1595-1596.	1.7	3
25	Clinical approach to autonomic dysfunction. Internal Medicine Journal, 2016, 46, 1134-1139.	0.5	13
26	Droxidopa and Reduced Falls in a Trial of Parkinson Disease Patients With Neurogenic Orthostatic Hypotension. Clinical Neuropharmacology, 2016, 39, 220-226.	0.2	49
27	Validation of a questionnaire for orthostatic hypotension for routine clinical use. Geriatrics and Gerontology International, 2016, 16, 785-790.	0.7	10
28	Use of Oral Droxidopa to Improve Arterial Pressure and Reduce Vasoactive Drug Requirements During Persistent Vasoplegic Syndrome After Cardiac Transplantation. Journal of Cardiothoracic and Vascular Anesthesia, 2016, 30, 1624-1626.	0.6	6
30	Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension. Clinical Autonomic Research, 2016, 26, 171-180.	1.4	41
31	Interventional trials in atypical parkinsonism. Parkinsonism and Related Disorders, 2016, 22, S82-S92.	1.1	19
32	Cardiovascular Safety of Droxidopa in Patients With Symptomatic Neurogenic Orthostatic Hypotension. American Journal of Cardiology, 2017, 119, 1111-1115.	0.7	14
33	The Treatment of Primary Orthostatic Hypotension. Annals of Pharmacotherapy, 2017, 51, 417-428.	0.9	39
34	2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope. Heart Rhythm, 2017, 14, e155-e217.	0.3	163
35	2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary. Journal of the American College of Cardiology, 2017, 70, 620-663.	1.2	131
36	2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope. Journal of the American College of Cardiology, 2017, 70, e39-e110.	1.2	231
37	2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: Executive summary. Heart Rhythm, 2017, 14, e218-e254.	0.3	27

#	ARTICLE	IF	CITATIONS
38	2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i> , 2017, 136, e25-e59.	1.6	215
39	2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients With Syncope: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Circulation</i> , 2017, 136, e60-e122.	1.6	189
40	Treatment of Nonmotor Symptoms in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 361-379.	0.9	15
41	Targeting the norepinephrinergic system in Parkinson's disease and related disorders: The locus coeruleus story. <i>Neurochemistry International</i> , 2017, 102, 22-32.	1.9	95
42	Droxidopa for Symptomatic Neurogenic Hypotension. <i>Cardiology in Review</i> , 2017, 25, 241-246.	0.6	2
43	Small fiber neuropathy. <i>Current Opinion in Pulmonary Medicine</i> , 2017, 23, 447-457.	1.2	45
44	Orthostatic hypotension: A review. <i>Nephrologie Et Therapeutique</i> , 2017, 13, S55-S67.	0.2	72
45	Multiple System Atrophy - State of the Art. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 41.	2.0	27
46	Multiple system atrophy: insights into a rare and debilitating movement disorder. <i>Nature Reviews Neurology</i> , 2017, 13, 232-243.	4.9	128
47	The Pharmacology of Autonomic Failure: From Hypotension to Hypertension. <i>Pharmacological Reviews</i> , 2017, 69, 53-62.	7.1	29
48	The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. <i>Journal of Neurology</i> , 2017, 264, 1567-1582.	1.8	311
49	Pharmacotherapy of Cardiovascular Autonomic Dysfunction in Parkinson Disease. <i>CNS Drugs</i> , 2017, 31, 975-989.	2.7	11
50	Evidence-based treatment of neurogenic orthostatic hypotension and related symptoms. <i>Journal of Neural Transmission</i> , 2017, 124, 1567-1605.	1.4	74
51	New perspectives on study designs for evaluating neuroprotection in Parkinson's disease. <i>Movement Disorders</i> , 2017, 32, 1365-1370.	2.2	12
52	Droxidopa in the Treatment of Postural Orthostatic Tachycardia Syndrome. <i>American Journal of Therapeutics</i> , 2017, 24, e157-e161.	0.5	34
53	Stratification of disease progression in a broad spectrum of degenerative cerebellar ataxias with a clustering method using MRI-based atrophy rates of brain structures. <i>Cerebellum and Ataxias</i> , 2017, 4, 9.	1.9	6
54	Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension. <i>BMC Neurology</i> , 2017, 17, 90.	0.8	65
55	Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects. <i>Drugs in R and D</i> , 2018, 18, 77-86.	1.1	7

#	ARTICLE	IF	CITATIONS
56	2018 ESC Guidelines for the diagnosis and management of syncope. <i>European Heart Journal</i> , 2018, 39, 1883-1948.	1.0	1,200
57	Refractory orthostatic hypotension in a patient with a spinal cord injury: Treatment with droxidopa. <i>Journal of Spinal Cord Medicine</i> , 2018, 41, 115-118.	0.7	3
58	Orthostatic Hypotension. , 2018, , 393-397.		0
59	Impact of the Norepinephrine Prodrug Droxidopa on the QTc Interval in Healthy Individuals. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 332-340.	0.8	6
60	Simultaneous voltammetric determination of droxidopa, acetaminophen, and tyrosine on hematoxylin and graphene oxide/ZnO nanocomposite-modified glassy carbon electrode. <i>Ionics</i> , 2018, 24, 1487-1495.	1.2	8
61	Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson Disease. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 627-634.	0.8	13
62	Orthostatic Hypotension. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1294-1309.	1.2	170
64	A patient with autonomic imbalance. <i>Nurse Practitioner</i> , 2018, 43, 18-22.	0.2	1
65	Standing and Supine Blood Pressure Outcomes Associated With Droxidopa and Midodrine in Patients With Neurogenic Orthostatic Hypotension: A Bayesian Meta-analysis and Mixed Treatment Comparison of Randomized Trials. <i>Annals of Pharmacotherapy</i> , 2018, 52, 1182-1194.	0.9	22
66	Pediatric Rheumatology Collaborative Study Group " over four decades of pivotal clinical drug research in pediatric rheumatology. <i>Pediatric Rheumatology</i> , 2018, 16, 45.	0.9	35
67	Orthostatic Hypotension in the Hypertensive Patient. <i>American Journal of Hypertension</i> , 2018, 31, 1255-1259.	1.0	41
68	Pharmacotherapy for postural tachycardia syndrome. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2018, 215, 28-36.	1.4	55
69	Initiation of droxidopa during hospital admission for management of refractory neurogenic orthostatic hypotension in severely ill patients. <i>Journal of Clinical Hypertension</i> , 2019, 21, 1308-1314.	1.0	17
70	A Stage-Based Approach to Therapy in Parkinson's Disease. <i>Biomolecules</i> , 2019, 9, 388.	1.8	41
71	<p>Role of nurses and nurse practitioners in the recognition, diagnosis, and management of neurogenic orthostatic hypotension: a narrative review</p>. <i>International Journal of General Medicine</i> , 2019, Volume 12, 173-184.	0.8	7
72	Nabilone for non-motor symptoms of Parkinson's disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study). <i>Journal of Neural Transmission</i> , 2019, 126, 1061-1072.	1.4	16
73	Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 635-645.	0.9	10
74	Autonomic dysfunction: Diagnosis and management. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2019, 167, 123-137.	1.0	23

#	ARTICLE	IF	CITATIONS
75	Multiple system atrophy. <i>International Review of Neurobiology</i> , 2019, 149, 137-192.	0.9	74
76	Cognitive and Behavioral Changes in Patients Treated With Droxidopa for Neurogenic Orthostatic Hypotension: A Retrospective Review. <i>Cognitive and Behavioral Neurology</i> , 2019, 32, 179-184.	0.5	5
77	Novel Therapeutic Options in the Management of Reflex Syncope. <i>American Journal of Therapeutics</i> , 2019, 26, e268-e275.	0.5	0
78	Chemical pharmacotherapy for the treatment of orthostatic hypotension. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 187-199.	0.9	18
79	Available and future treatments for atypical parkinsonism. A systematic review. <i>CNS Neuroscience and Therapeutics</i> , 2019, 25, 159-174.	1.9	22
80	Substantial renal conversion of l-threo-3,4-dihydroxyphenylserine (droxidopa) to norepinephrine in patients with neurogenic orthostatic hypotension. <i>Clinical Autonomic Research</i> , 2019, 29, 113-117.	1.4	6
81	Cardiovascular Disorders Mediated by Autonomic Nervous System Dysfunction. <i>Cardiology in Review</i> , 2020, 28, 65-72.	0.6	14
82	Longitudinal Multi-omics Reveals Subset-Specific Mechanisms Underlying Irritable Bowel Syndrome. <i>Cell</i> , 2020, 182, 1460-1473.e17.	13.5	217
83	Management of Orthostatic Hypotension, Postprandial Hypotension, and Supine Hypertension. <i>Seminars in Neurology</i> , 2020, 40, 515-522.	0.5	12
84	Current Management and Emerging Therapies in Multiple System Atrophy. <i>Neurotherapeutics</i> , 2020, 17, 1582-1602.	2.1	11
85	Addressing Orthostatic Hypotension in Heart Failure: Pathophysiology, Clinical Implications and Perspectives. <i>Journal of Cardiovascular Translational Research</i> , 2020, 13, 549-569.	1.1	9
86	Neurogenic Orthostatic Hypotension: State of the Art and Therapeutic Strategies. <i>Clinical Medicine Insights: Cardiology</i> , 2020, 14, 117954682095341.	0.6	8
87	Drug-Related Orthostatic Hypotension: Beyond Anti-Hypertensive Medications. <i>Drugs and Aging</i> , 2020, 37, 725-738.	1.3	62
88	Clinical Trials for Neurogenic Orthostatic Hypotension: A Comprehensive Review of Endpoints, Pitfalls, and Challenges. <i>Seminars in Neurology</i> , 2020, 40, 523-539.	0.5	7
89	Cardiovascular Safety Considerations in the Treatment of Neurogenic Orthostatic Hypotension. <i>American Journal of Cardiology</i> , 2020, 125, 1582-1593.	0.7	15
90	State-of-the-art pharmacotherapy for autonomic dysfunction in Parkinson's disease. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 445-457.	0.9	9
91	Pharmacokinetics of Amprexetine, a Norepinephrine Reuptake Inhibitor, in Healthy Subjects and Adults with Attention-Deficit/Hyperactive Disorder or Fibromyalgia Pain. <i>Clinical Pharmacokinetics</i> , 2021, 60, 121-131.	1.6	3
92	Characterization of the changes in supine blood pressure with long-term use of droxidopa in patients with neurogenic orthostatic hypotension. <i>Health Science Reports</i> , 2021, 4, e227.	0.6	1

#	ARTICLE	IF	CITATIONS
93	The Pathogenesis and Treatment of Cardiovascular Autonomic Dysfunction in Parkinson's Disease: What We Know and Where to Go. , 2021, 12, 1675.		17
94	Droxidopa Persistence in Neurogenic Orthostatic Hypotension May Be Affected by Titration Approach. International Journal of General Medicine, 2021, Volume 14, 4485-4490.	0.8	2
95	Gut Microbiota-Derived Metabolites in Irritable Bowel Syndrome. Frontiers in Cellular and Infection Microbiology, 2021, 11, 729346.	1.8	65
96	Awakening Blood Pressure Rise in a Patient with Spinal Cord Injury. American Journal of Case Reports, 2016, 17, 177-181.	0.3	3
97	The Diagnosis and Management of Cardiovascular Autonomic Dysfunction and Disease. , 2017, , 37-66.		0
98	Pure Autonomic Failure: Diagnosis, Differential Diagnosis, and Natural History. Contemporary Endocrinology, 2018, , 173-182.	0.3	0
99	2018 KHRS guideline for the evaluation and management of syncope-Part 1. International Journal of Arrhythmia, 2018, 19, 126-144.	0.3	0
101	Clinical management of neurogenic orthostatic hypotension. Annals of Movement Disorders, 2019, 2, 91.	0.3	0
102	for Orthostatic in Parkinson's and Other. Neuromethods, 2021, , 323-365.	0.2	0
104	Orthostatic hypotension. Part 2: diagnosis and treatment. Innovative Medicine of Kuban, 2020, , 77-85.	0.0	0
105	Multiple System Atrophy – Cerebellar Type: Clinical Picture and Treatment of an Often-Overlooked Disorder. Cureus, 2020, 12, e10741.	0.2	7
106	Ambulatory blood pressure and drug treatment for orthostatic hypotension as predictors of mortality in patients with multiple system atrophy. European Journal of Neurology, 2021, , .	1.7	6
107	Durability of the Clinical Benefit of Droxidopa for Neurogenic Orthostatic Hypotension During 12 Weeks of Open-Label Treatment. Neurology and Therapy, 2022, 11, 459-469.	1.4	4
108	New approaches to treatments for sleep, pain and autonomic failure in Parkinson's disease - Pharmacological therapies. Neuropharmacology, 2022, 208, 108959.	2.0	7
109	Update on Parkinson's Disease Therapy. Touch Reviews in Neurology, 2021, 17, 92.	0.1	1
110	Microbial Metabolite Regulation of Epithelial Cell-Cell Interactions and Barrier Function. Cells, 2022, 11, 944.	1.8	15
111	Orthostatic Hypotension: Management of a Complex, But Common, Medical Problem. Circulation: Arrhythmia and Electrophysiology, 2022, 15, CIRCEP121010573.	2.1	25
112	Effects of Nabilone on Sleep Outcomes in Patients with Parkinson's Disease: A Post-hoc Analysis of NMS Study. Movement Disorders Clinical Practice, 2022, 9, 751-758.	0.8	10

#	ARTICLE	IF	CITATIONS
113	Symptomatic Care in Multiple System Atrophy: State of the Art. <i>Cerebellum</i> , 2023, 22, 433-446.	1.4	7
114	Scoping Review of Randomized Trials With Discontinuation of Medicines in Older Adults. <i>Journal of the American Medical Directors Association</i> , 2022, 23, 1926.e11-1926.e35.	1.2	2
115	Droxidopa for the Treatment of Parkinsonâ€™s Disease. , 2022, , 3365-3373.		0
117	Droxidopa. , 2023, , 721-727.		0
119	Autonomic Dysfunction and Orthostatic Hypotension. , 2024, , 466-475.		0